Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
21.5M
-
Number of holders
-
149
-
Total 13F shares, excl. options
-
18M
-
Shares change
-
-388K
-
Total reported value, excl. options
-
$927M
-
Value change
-
-$30.9M
-
Put/Call ratio
-
1.27
-
Number of buys
-
77
-
Number of sells
-
-77
-
Price
-
$51.43
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock (ENTA) as of Q1 2020
190 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock as of Q1 2020.
ENANTA PHARMACEUTICALS INC - Common Stock (ENTA) has 149 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18M shares
of 21.5M outstanding shares and own 83.88% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.83M shares), FARALLON CAPITAL MANAGEMENT LLC (1.75M shares), VANGUARD GROUP INC (1.69M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.35M shares), STATE STREET CORP (908K shares), RENAISSANCE TECHNOLOGIES LLC (881K shares), DIMENSIONAL FUND ADVISORS LP (716K shares), Krensavage Asset Management, LLC (700K shares), ARMISTICE CAPITAL, LLC (568K shares), and FIRST MANHATTAN CO (412K shares).
This table shows the top 149 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.